changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
Explore how you can apply this unique therapy in your free-standing center
Discover how absorbed radiation dose to tumor maximizes necrosis without compromising patient safety 3-6, 13
Discover a simple way to calculate and order your next TheraSphere® dose vial
Stop Exposing Yourself To Unnecessary Radiation
Some liver cancer treatments work through their embolic properties. TheraSphere® utilizes radiation as its primary mode of action to destroy tumor tissue.1 The high activity of glass microspheres makes TheraSphere® microembolic and preserves normal parenchymal flow since fewer microspheres are needed to achieve the desired absorbed dose.1,3,5,7,11,45
High absorbed dose coverage should be the goal of treatment with y90 radioembolization. Influenced by the combined effects of microsphere coverage and administered activity, a greater absorbed dose to tumor with TheraSphere® leads to improved outcomes above certain absorbed dose thresholds without compromising patient safety.1,2,5,6,39,43
TheraSphere® offers the flexibility to optimize absorbed dose to the tumor to meet individual patient treatment goals in both the curative and palliative settings. This enables clinical utility for downstaging, bridge to transplant, radiation segmentectomy and portal vein thrombosis.8,9,40,44
TheraSphere® yields tumor necrosis using radiation as the primary mechanism of action, with a microembolic effect.1,6
High activity TheraSphere® glass microspheres deliver greater tumor absorbed dose coverage while resin has greater microsphere coverage.43
More complete pathologic necrosis is observed when the delivered dose is >190 Gy in ≤2 segments6
56.5 months (includes transplanted patients)
34.5 months (excludes transplanted patients)
* Total dose to the liver does not exceed 150 Gy.
Recommendations for personalised HCC tre...
Radioembolization treatment for primary ...
OPTALYSE PE Results Presented at Society...
Healthcare Player BTG on lookout for acq...
NICE highlights potential role of TheraS...